Akero Therapeutics (AKRO) Up on Positive Data from NASH Study

This article was originally published on Nasdaq

Akero Therapeutics’ AKRO shares skyrocketed 136.76% during market hours on Sep 13 after the company announced positive top-line data from its phase IIB HARMONY study. The study evaluated the safety and efficacy of efruxifermin (EFX) in patients with pre-cirrhotic non-alco